Integra LifeSciences Holdings Corporation (IART) Receiving Somewhat Favorable News Coverage, Analysis Finds
Media headlines about Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra LifeSciences Holdings Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the life sciences company an impact score of 44.8758190467096 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at $46.71 on Thursday. The firm has a market cap of $3,757.50, a PE ratio of 26.45, a PEG ratio of 2.08 and a beta of 0.64. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.35% and a net margin of 4.52%. Integra LifeSciences Holdings Corporation’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.93 EPS. equities research analysts expect that Integra LifeSciences Holdings Corporation will post 1.87 EPS for the current fiscal year.
Several analysts have commented on IART shares. Zacks Investment Research lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Barclays PLC reaffirmed an “equal weight” rating and issued a $53.00 price objective (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. BidaskClub lowered shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, September 18th. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $53.82.
TRADEMARK VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Receiving Somewhat Favorable News Coverage, Analysis Finds” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/16/integra-lifesciences-holdings-corporation-iart-receiving-somewhat-favorable-news-coverage-analysis-finds.html.
In other news, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the transaction, the vice president now owns 21,665 shares in the company, valued at $1,022,371.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara B. Hill bought 10,768 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Tuesday, October 31st. The stock was acquired at an average price of $46.66 per share, with a total value of $502,434.88. Following the purchase, the director now directly owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by company insiders.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Stock Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related stocks with our FREE daily email newsletter.